During the last session, Ovid Therapeutics Inc (NASDAQ:OVID)’s traded shares were 0.31 million, with the beta value of the company hitting 0.28. At the end of the trading day, the stock’s price was $0.73, reflecting an intraday gain of 3.42% or $0.02. The 52-week high for the OVID share is $4.10, that puts it down -461.64 from that peak though still a striking 6.85% gain since the share price plummeted to a 52-week low of $0.68. The company’s market capitalization is $52.13M, and the average intraday trading volume over the past 10 days was 0.54 million shares, and the average trade volume was 300.63K shares over the past three months.

Ovid Therapeutics Inc (OVID) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.44. OVID has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.17.

Ovid Therapeutics Inc (NASDAQ:OVID) trade information

Ovid Therapeutics Inc (OVID) registered a 3.42% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.42% in intraday trading to $0.73, hitting a weekly high. The stock’s 5-day price performance is 0.56%, and it has moved by -26.52% in 30 days. Based on these gigs, the overall price performance for the year is -78.41%. The short interest in Ovid Therapeutics Inc (NASDAQ:OVID) is 0.69 million shares and it means that shorts have 2.28 day(s) to cover.

The consensus price target of analysts on Wall Street is $8, which implies an increase of 90.88% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $11 respectively. As a result, OVID is trading at a discount of -1406.85% off the target high and -310.96% off the low.

Ovid Therapeutics Inc (OVID) estimates and forecasts

Statistics show that Ovid Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Ovid Therapeutics Inc (OVID) shares have gone down -27.32% during the last six months, with a year-to-date growth rate more than the industry average at 45.95% against 16.50. In the rating firms’ projections, revenue will increase 68.02% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 187.5k as predicted by 6 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 100k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 141.56k and 148k respectively. In this case, analysts expect current quarter sales to grow by 32.45% and then drop by -32.43% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.87%. While earnings are projected to return 37.16% in 2025, the next five years will return 23.13% per annum.

OVID Dividends

Ovid Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Ovid Therapeutics Inc (NASDAQ:OVID)’s Major holders

Ovid Therapeutics Inc insiders own 15.90% of total outstanding shares while institutional holders control 56.32%, with the float percentage being 66.97%. RUBRIC CAPITAL MANAGEMENT LP is the largest shareholder of the company, while 104.0 institutions own stock in it. As of 2024-06-30, the company held over 5.32 million shares (or 7.5173% of all shares), a total value of $4.09 million in shares.

The next largest institutional holding, with 4.08 million shares, is of MADISON AVENUE PARTNERS, LP’s that is approximately 5.7725% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.14 million.

Also, the Mutual Funds coming in first place with the largest holdings of Ovid Therapeutics Inc (OVID) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.79 shares. This amounts to just over 2.52 percent of the company’s overall shares, with a $1.32 million market value. The same data shows that the other fund manager holds slightly less at 1.61, or about 2.26% of the stock, which is worth about $1.18 million.